Affymetrix licenses Hematide to Takeda
USA-based pharmaceutical firm Affymetrix and Japanese drugmaker Takeda, say they have entered into an agreement to develop and commercialize the former's lead anemia drug candidate Hematide, a synthetic peptide erythropoiesis stimulating agent, in Japan.
Under the terms of the deal, Takeda will pay the Palo Alto, California-headquartered firm $17.0 million in upfront payments, and will also purchase $10.0 million of Affymetrix stock. The US firm is also set to receive regulatory and milestone payments totalling around $75.0 million as the product is developed, and double-digit royalties if it is successfully commercialized in Japan.
The companies added that erythropoiesis stimulating agents such as Hematide have been successfully used to treat anemia in cancer patients, adding that there is currently a $12.0 billion worldwide market for anemia drugs, with the Japanese market worth $1.0 billion a year.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze